Bladder cancer

ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer

Z. C. Xu, Cai, H. Z., Li, X., Xu, W. Z., Xu, T., Yu, B., Zou, Q., Xu, L., Xu, Z. C., Cai, H. Z., Li, X., Xu, W. Z., Xu, T., Yu, B., Zou, Q., and Xu, L., ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer, vol. 15, p. -, 2016.

This study aims to investigate the association between ERCC1 codon C118T polymorphism and the response rate of platinum-based chemotherapy in patients with late-stage bladder cancer. A total of 41 eligible patients histologically confirmed as having stage IV muscle-invasive transitional cell carcinoma of the bladder were treated with platinum-based chemotherapy for 2-6 cycles. The genotypes of patients were determined by PCR amplification of genomic DNA followed by restriction enzyme digestion. Positive responses were categorized as complete and partial responses.

CYP1A2-163C/A (rs762551) polymorphism and bladder cancer risk: a case-control study

Y. L. Song, Wang, L., Ren, J. C., Xu, Z. H., Song, Y. L., Wang, L., Ren, J. C., Xu, Z. H., Song, Y. L., Wang, L., Ren, J. C., and Xu, Z. H., CYP1A2-163C/A (rs762551) polymorphism and bladder cancer risk: a case-control study, vol. 15, p. -, 2016.

To date, no study has investigated the association between CYP1A2-163C/A polymorphism and bladder cancer risk in a Chinese population. Here, we extracted genomic DNA from peripheral white blood cells, and differentiated CYP1A2 alleles by polymerase chain reaction-based restriction fragment length polymorphism methods. Differences in genotype frequencies between the cases and controls were evaluated using a chi-square test. The odds ratio (OR) and its 95% confidence interval (CI) were calculated using an unconditional logistic regression model.

Subscribe to Bladder cancer